Fourthly, although FAEs are prospectively collected for each individual study, this analysis is retrospective, and there are potentially important differences among the studies, including differing tumor types, dosage and administration schedule of mTOR inhibitors, periods of study conduct and study investigators. The gene discussed is MTOR; the disease is neoplasm.